The research program funded by R01 013806 is focused on liver fibrosis progression in HIV/HCV coinfected persons. Liver disease is one of the leading causes of death in HIV infected persons, and its public health importance is expected to increase. As treatments for both HIV and HCV improve, the important clinical questions now are treatment-related. Does antiretroviral therapy (ART) affect progression of liver disease and therefore need to be given to HIV/HCV coinfected persons even at high CD4+ lymphocyte counts? Is suppression of HCV replication by treatment sufficient to stop fibrosis progression? Does the chronic immune activation caused by HIV contribute to IFN resistance and can ART diminish that effect? In the next funding cycle, we plan to answer these and other questions related to the """"""""treated"""""""" history of HIV/HCV coinfected persons by a series of integrated clinical and laboratory studies that build on the models of natural history and pathogenesis that we and others have developed over the past decade.
The specific aims are as follows:
Aim 1 is to test the hypothesis that effective antiretroviral therapy reduces progression of liver fibrosis in HIV/HCV coinfected persons.
Aim 2 is to test the hypothesis that suppression of HCV replication by treatment reduces liver fibrosis progression in HIV/HCV coinfected persons.
Aim 3 is to test the hypothesis that interferon alfa (IFN) sensitivity is improved by antiretroviral therapy.
The aims of prior funding cycles have been accomplished and reported among 25 peer reviewed articles supported by R01 013806. The current aims are revised to answer significant scientific questions during the next period using innovative research tools. There is a high likelihood that these studies will inform U.S. Public Health Service guidelines on when to start antiretroviral therapy and provide a scientific basis for existing guidelines governing treatment of HCV infection in persons with HIV.
The proposed research is designed to guide significant clinical decisions, such as when to start antiretroviral therapy in the 25% of HIV infected persons who have chronic hepatitis C and whether treatment for HCV infection can be justified to prevent progression of liver disease. The studies might also explain why treatments for chronic hepatitis C are not as effective in persons dually infected with HIV.
|Cepeda, Javier A; Solomon, Sunil S; Srikrishnan, Aylur K et al. (2016) Serum Fibrosis Markers for the Diagnosis of Liver Disease Among People With Chronic Hepatitis C in Chennai, India. Open Forum Infect Dis 3:ofw156|
|Falade-Nwulia, O; Mehta, S H; Lasola, J et al. (2016) Public health clinic-based hepatitis C testing and linkage to care in Baltimore. J Viral Hepat 23:366-74|
|Mehta, Shruti H; Thomas, David L (2016) Doing the math on hepatitis C virus treatment. J Hepatol 65:5-6|
|Wasilewski, Lisa N; El-Diwany, Ramy; Munshaw, Supriya et al. (2016) A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies. J Virol 90:3773-82|
|Patel, Eshan U; Cox, Andrea L; Mehta, Shruti H et al. (2016) Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection. J Infect Dis 214:344-52|
|Hsieh, Yu-Hsiang; Rothman, Richard E; Laeyendecker, Oliver B et al. (2016) Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department. Clin Infect Dis 62:1059-65|
|Bailey, Justin R; Dowd, Kimberly A; Snider, Anna E et al. (2015) CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus. J Infect Dis 212:914-23|
|El-Diwany, Ramy; Wasilewski, Lisa N; Witwer, Kenneth W et al. (2015) Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating MicroRNAs That Are Associated with Nonlytic Hepatocyte Release. J Virol 89:9454-64|
|Bailey, Justin R; Wasilewski, Lisa N; Snider, Anna E et al. (2015) Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest 125:437-47|
|Konerman, Monica A; Mehta, Shruti H; Sutcliffe, Catherine G et al. (2014) Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 59:767-75|
Showing the most recent 10 out of 22 publications